Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV)

References

• Morral N. Novel targets and therapeutic strategies for type 2 diabetes. Trends Endocrinol Metab 2003; 14:169–75.
   PubMed Web of Science ®Google Scholar
• Ross S A, Gulve E A, and Wang M. Chemistry and biochemistry of Type 2 Diabetes. Chem Rev. 2004; 104 (3):1255–1282.
   PubMedGoogle Scholar
• Skyler JS. Diabetes Mellitus: Pathogenesis and Treatment Strategies. J Med Chem. 2004; 47: 4113–4117.
   PubMed Web of Science ®Google Scholar
• Vilsbøll T, Knop FK. Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus. Ugeskr Laeger 2007; 169: 2101–5.
   PubMedGoogle Scholar
• Drucker DJ. The biology of incretin hormones. Cell Metabolism 2006; 3:153–165.
   PubMed Web of Science ®Google Scholar
• Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993; 76: 912–917.
   PubMed Web of Science ®Google Scholar
• Lynn FC, Pamir N, Ng EHC, McIntosh CH.S, Pederson RA. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001; 50:1004–1011.
   PubMed Web of Science ®Google Scholar
• Jones I R, Owens DR, Moody A J, Luzio SD; Morris T, Hayes, TM. The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion. Diabetologia 1987; 30: 707–712.
   PubMedGoogle Scholar
• Meier JJ, Hucking K, Holst JJ, Deacon CF, Schmiegel WH, Nauck MA. Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes. Diabetes 2001; 50: 2497–2504.
   PubMed Web of Science ®Google Scholar
• Knudsen LB. Glucagon-like Peptide-1: The Basis of New Class of Treatment for Type 2 Diabetes. J Med Chem 2004; 47: 4128–4134.
   PubMed Web of Science ®Google Scholar
• Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin 4, an exendin 3 analogue from Heloderma suspectum venom. J Biol Chem 1992; 267: 7402–7405.
   PubMed Web of Science ®Google Scholar
• Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 1993; 214: 829–835.
   PubMedGoogle Scholar
• Kieffer TJ, McIntosh CH, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995; 136: 3585–3596.
   PubMed Web of Science ®Google Scholar
• Hansen L, Deacon CF, Orskov C, Holst JJ. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999; 140: 5356–5363.
   PubMed Web of Science ®Google Scholar
• Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999; 85: 9–24.
   PubMed Web of Science ®Google Scholar
• http://accelrys.com/products/accord/desktop/tsar.html: TSAR 3.3, Oxford Molecular Limited
   Google Scholar
• Takashi K, Sugimoto I, Nekado T, Ochi K, Ohtani T, Tajima Y, Yamamoto S, Kawabata K, Nakai H. Toda M (2007) Design and synthesis of long-acting inhibitors of Dipeptidyl peptidase IV. Biorg Med Chem 2007; 15: 2715–2735.
   PubMedGoogle Scholar
• Takashi K, Sugimoto I, Nekado T, Ochi K, Takai S, Kinoshita A, Hatayama A, Yamamoto S, Kawabata K, Nakai H., Toda M. Discovery of long-acting N-(cyanomethyl)-N-alkyl-L-prolinamide inhibitors of dipeptidyl peptidase IV. Biorg Med Chem 2008; 16: 190–208.
   PubMedGoogle Scholar
• Takashi K, Sugimoto I, Nekado T, Ochi K, Takai S, Kinoshita A, Hatayama A, Yamamoto S, Kishikawa K, Nakai H., Toda M. Design and synthesis of DPP IV inhibitors lacking the electrophilic nitrile group. Biorg Med Chem 2008; 16: 1613–1631.
   PubMedGoogle Scholar
• Sadowski J, Gasteiger J. From Atoms and Bonds to Three-Dimensional Atomic Coordinates: Automatic Model Builders. Chem Rev 1993; 93: 2567–2581.
   Web of Science ®Google Scholar
• Benfenati E, Quantitative structure activity relationships [QSAR]. for pesticide regulatory purposes. Elsevier 2007:186.
   Google Scholar
• Balakrishnan N; Childs A. “Outlier”, in Hazewinkel, Michiel, Encyclopaedia of Mathematics, 2001, Kluwer Academic Publishers, ISBN 978-1556080104
   Google Scholar
• Kim KH. Outliers in SAR and QSAR: 2. Is a flexible binding site a possible source of outliers? J Comput Aided Mol Des 2007; 21: 421–435.
   PubMedGoogle Scholar
• Spanier A M, Okai H, Tamura M. Food Flavor and Safety: Molecular Analysis and Design. ACS Symposium Series 1993; 103–104.
   Google Scholar
• Paliwal S, Narayan A, Paliwal Shailendra. Quantitative Structure Activity Relationship Analysis of Dicationic Diphenylisoxazole as Potent Anti-Trypanosomal Agents. QSAR Comb Sci 2009; 28: 1367 – 1375.
   Google Scholar
• Kohavi, Ron. A study of cross-validation and bootstrap for accuracy estimation and model selection. Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence 1995; 2 (12): 1137–1143. (Morgan Kaufmann, San Mateo).
   Google Scholar
• Chang J, Luo Y, Su, K. GPSM: a Generalized Probabilistic Semantic Model for ambiguity resolution. In Proceedings of the 30th Annual Meeting on Association For Computational Linguistics (Newark, Delaware, June 28 - July 02, 1992). Annual Meeting of the ACL. Association for Computational Linguistics, Morristown, NJ,1992; 177–184.
   Google Scholar
• Devijver P A, Kittler J. Pattern Recognition: A Statistical Approach, Prentice-Hall, London, 1982
   Google Scholar
• Quinn RJ, Carroll AR, Pham NB, Baron P, Palframan ME, Suraweera L, Pierens GK, Muresan M. Developing a Drug-like Natural Product Library. J Nat Prod 2008; 71: 464–468.
   PubMed Web of Science ®Google Scholar
• Dessalew N. QSAR study on aminophenylbenzamides and acrylamides as histone deacetylase inhibitors: An insight into the structural basis of antiproliferative activity. Med Chem Res 2007; 16:449–460.
   Web of Science ®Google Scholar
• Paliwal SK, Pal M, Siddiqui AA. Quantitative structure activity relationship analysis of angiotensin II AT1 receptor antagonists. Med Chem Res DOI 10.1007/s00044-009-9205-9.
   Google Scholar
• Karelson M. Molecular Descriptors in QSAR / QSPR, Wiley Interscience, New York, February. 2000.
   Google Scholar
• Peters, Jens-Uwe. 11 years of Cyanopyrrolidines as DPP-IV Inhibitors. Current topics in Med Chem 2007;7: 579–595.
   PubMed Web of Science ®Google Scholar
• Hall L H, Kier LB. The molecular connectivity chi indexes and kappa shape indexes in structure-property modeling. Reviews in Computational Chemistry II 1991; 367–422.
   Google Scholar
• Sapre NS, Pancholi N, Gupta S, Sapre N. Computational modeling of tetrahydroimidazo-[4,5,1-jk][1,4]. benzodiazepinone derivatives: an atomistic drug design approach using Kier-Hall electrotopological state (E-state) indices. J Comput Chem 2008; 29: 1699–706.
   PubMed Web of Science ®Google Scholar